The role of tumor destroying enzymes in cancer treatment

Cancer, believed to date back around 120,000 years, is described as uncontrolled and abnormal cell growth. According to data from the World Health Organization (WHO) and the American Cancer Society (ACS) database in 2018, approximately 22.4% of male cancer patients and 18.2% of female cancer patients are within the age range of 0 to 74 years. In 2018, the most common cancers were lung cancer (2.09 million cases), breast cancer (2.09 million cases), and prostate cancer (1.28 million cases). Lung, liver, and stomach cancers are the deadliest. Among many types of cancer, lung, breast, colorectal, stomach, prostate, and liver cancers accounted for about 55% of global incidences in 2012, and these were selected as the main types of cancer. Although the exact mechanism of cancer formation is unknown, it is clear that cells that require apoptosis continue to grow rapidly and uncontrollably. According to evidence from the Human Genome Project, cancer is genetically inherited and is characterized by mutations. The immune system interacts closely with tumors at all stages of cancer, much like with any disease. Immune and cancer cells share a symbiotic relationship that prevents and enhances tumor growth.

سرطان، که تصور می شود قدمت آن به حدود 120000 سال قبل باز می گردد، به عنوان رشد کنترل نشده و غیر طبیعی سلول ها توصیف می شود. بر اساس داده های سال

201۸ به دست آمده از سازمان بهداشت جهانی ( WHO )و پایگاه داده انجمن سرطان آمریکا( ACS ) ، تقریبا 22.۴ درصد بیماران سرطانی مرد و 1۸.2 درصد زنان در

محدوده سنی 0 تا ۷۴ سال وجود دارد. سرطان ریه ) 2.09 میلیون مورد(، سرطان سینه ) 2.09 میلیون مورد( و سرطان پروستات ) 1.2۸ میلیون مورد( شایع ترین سرطان ها

در سال 201۸ هستند. سرطان های ریه، کبد و معده کشنده ترین سرطان ها هستند. از میان بسیاری از